ArticleArab journal of urology2025
Safety & efficacy of thulium laser endoscopic en bloc resection versus conventional trans urethral resection of bladder tumors, for treatment of non muscle invasive bladder tumors: A prospective randomized trial.
Article in Arab journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative and oncological outcomes of thulium laser-ERBT versus conventional TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.Lasers in medical science · 2026Pooled it
- Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-muscle invasive bladder cancers (NMIBCs) are managed with endoscopic resection and intravesical therapy. Lasers, particularly thulium and holmium, are now central to bladder tumor management. This study assesses the safety and efficacy of thulium laser enucleation of bladder tumors (Tm-LRBT). Patients & Methods: A prospective randomized clinical study was conducted from June 2022 to December 2023, involving 100 patients. Group A was treated with TmLRBT and Group B with conventional monopolar TURBT. Informed consent was obtained from all participants. Inclusion criteria were NMIBC, tumor size < 5 cm, and fewer than three tumors. Exclusion criteria included tumors > 5 cm, more than three tumors, invasive/upper tract cancers, hydronephrosis, metastases, and history of TURBT. Results: The mean tumor diameter in Group A was 2.3 ± 0.74 cm. The mean operative time was 45.4 ± 13.48 minutes. Re-resection within 90 days was negative for bladder cancer in all Group A patients; three patients in Group B had persistent disease. Seven Group B cases lacked muscle in the specimen compared to three in Group A. Significant intraoperative bleeding occurred in four cases in Group A and five in Group B. Tumor recurrence was 42% in Group A and 44% in Group B at 12-month follow-up. . Conclusion: TmLRBT is a potential alternative to TURBT, providing accurate reporting of neoplastic depth invasion. It is advantageous, particularly for tumors in the lateral wall, bladder dome, or perimeatal zone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.